Jason Butler analyst JMP

Currently out of the existing stock ratings of Jason Butler, 218 are a BUY (95.2%), 10 are a HOLD (4.37%), 1 are a SELL (0.44%).

Jason Butler

Work Performance Price Targets & Ratings Chart

Analyst Jason Butler, currently employed at JMP, carries an average stock price target met ratio of 35.56% that have a potential upside of 50.92% achieved within 180 days.

Jason Butler’s has documented 458 price targets and ratings displayed on 41 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on ARGX, argenx NV ADR at 01-Nov-2024.

Wall Street Analyst Jason Butler

Analyst best performing recommendations are on TRVN (TREVENA).
The best stock recommendation documented was for HALO (HALOZYME THERAPEUTICS) at 2/24/2021. The price target of $48 was fulfilled within 1 day with a profit of $3.45 (6.71%) receiving and performance score of 67.06.

Average potential price target upside

ACAD ACADIA Pharmaceuticals ADMS Adamas Pharmaceuticals ARGX argenx NV ADR ARNA Arena Pharmaceuticals AXGT Sio Gene Therapies CRMD CorMedix CYTK Cytokinetics ESPR Esperion Therapeutics HALO Halozyme Therapeutics ITCI Intracellular Th KRTX Karuna Therapeutics NEOS Neos Therapeutics NERV Minerva Neurosciences RZLT Rezolute SYRS Syros Pharmaceuticals VNDA Vanda Pharmaceuticals XON Precigen ZFGN Zafgen MYOV Myovant Sciences Ltd PLXP PLx Pharma AMTI Applied Molecular Transport  AQST Aquestive Therapeutics ATHA Athira Pharma  AXON Axon Enterprise . CRTX Cortexyme ENTA Enanta Pharmaceuticals HOOK Hookipa Pharma LRMR Larimar Therapeutics PGEN Precigen GMDA Gamida Cell Ltd MRNS Marinus Pharmaceuticals CNCE Concert Pharmaceuticals MOR MorphoSys AG ADR OVID Ovid Therapeutics PRTO Proteon Therapeutics QNRX Quoin Pharmaceuticals Ltd DRC TRVN Trevena VRDN Viridian Therapeutics ZGNX Zogenix GHRS GH Research PLC PRTA Prothena plc

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$27

$10.58 (64.43%)

$27

15 days ago
(07-Nov-2024)

8/22 (36.36%)

$9.79 (56.89%)

119

Buy

$28

$11.58 (70.52%)

$28

15 days ago
(07-Nov-2024)

0/4 (0%)

$10.79 (62.70%)

Hold

1 months 12 days ago
(10-Oct-2024)

11/14 (78.57%)

$9.98 (39.89%)

141

Buy

$23

$6.58 (40.07%)

$30

3 months 14 days ago
(08-Aug-2024)

0/3 (0%)

$7.28 (46.31%)

Buy

$20

$3.58 (21.80%)

$28

3 months 15 days ago
(07-Aug-2024)

16/21 (76.19%)

$4.83 (31.84%)

184

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Jason Butler is most bullish on?

Potential upside of $41.77 has been obtained for ARGX (ARGENX NV ADR)

Which stock is Jason Butler is most reserved on?

Potential downside of $1.39 has been obtained for SYRS (SYROS PHARMACEUTICALS)

What Year was the first public recommendation made by Jason Butler?

On 2011

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?